Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date

References

• Uson Junior PLS, Bogenberger J, Borad MJ. Advances in the treatment of biliary tract cancers. Curr Opin Gastroenterol. 2020;36(2):85–89. doi:10.1097/MOG.0000000000000606
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599. doi:10.1634/theoncologist.2015-0446
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• D-Y O, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1:EVIDoa2200015.
   PubMedGoogle Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a Phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701. doi:10.1016/S1470-2045(21)00027-9
   PubMed Web of Science ®Google Scholar
• Yoo C, Kim K-P, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560–1572. doi:10.1016/S1470-2045(21)00486-1
   PubMed Web of Science ®Google Scholar
• Uson Junior PLS, Borad MJ. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. Exp Op Investig Drugs. 2022;31(1):125–131. doi:10.1080/13543784.2022.2017882
   PubMed Web of Science ®Google Scholar
• Berchuck JE, Facchinetti F, DiToro DF, et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Annals of Oncology. 2022;33(12):1269–1283. doi:10.1016/j.annonc.2022.09.150
   PubMed Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019;9:417. doi:10.3389/fonc.2019.00417
   PubMed Web of Science ®Google Scholar
• Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599–608. doi:10.1093/annonc/mdw013
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW, et al. Cancer cell metabolism. In: Cold Spring Harbor Symposia on Quantitative Biology. Vol. 76. Cold Spring Harbor Laboratory Press; 2011:85–95.
   Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi:10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487–494. doi:10.1007/s00401-010-0645-6
   PubMed Web of Science ®Google Scholar
• Chen T, Wu G, Hu H, et al. Enhanced fatty acid oxidation mediated by CPT1C promotes gastric cancer progression. J Gastrointest Oncol. 2020;11(4):695. doi:10.21037/jgo-20-157
   PubMed Web of Science ®Google Scholar
• Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a Phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711–720. doi:10.1016/S2468-1253(19)30189-X
   PubMed Web of Science ®Google Scholar
• Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation. JAMA Oncology. 2021;7(11):1669–1677. doi:10.1001/jamaoncol.2021.3836
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lance Oncol t. 2020;21(6):796–807. doi:10.1016/S1470-2045(20)30157-1
   PubMed Web of Science ®Google Scholar
• Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat. 1991;20(8):2609–2631. doi:10.1080/03610929108830654
   Google Scholar
• Cleary JM, Rouaisnel B, Daina A, et al. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. NPJ Prec Oncol. 2022;6(1):1–8.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12):1540–1547. doi:10.1158/2159-8290.CD-18-0877
   PubMed Web of Science ®Google Scholar
• Reinbold HIC, Rabe P, Rabe P, et al. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Comm. 2022;13(1):1–12. doi:10.1038/s41467-022-32436-4
   PubMed Web of Science ®Google Scholar
• Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆. Annals of Oncology. 2023;34(2):127–140. doi:10.1016/j.annonc.2022.10.506
   PubMed Web of Science ®Google Scholar
• Junior U, Luiz Serrano P, Bogenberger JM, et al. ”FGFR2-IIIb expression by immunohistochemistry has high specificity in cholangiocarcinoma with FGFR2 genomic alterations. Dig Dis Sci. 2022;67(8):3797–3805. doi:10.1007/s10620-021-07303-9
   PubMed Web of Science ®Google Scholar
• Zarei M, Hajihassani O, Hue JJ, et al. Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. J Exp Clin Cancer Res. 2022;41(1):1–18. doi:10.1186/s13046-022-02489-w
   PubMed Web of Science ®Google Scholar
• Zarei M, Hajihassani O, Hue JJ, et al. Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer. bioRxiv. 2023;2023:3.
   Google Scholar